Elongation factor-2 kinase: immunological evidence for the existence of tissue-specific isoforms  by Hait, William N. et al.
FEBS 17746 FEBS Letters 397 (1996) 55-60 
Elongation factor-2 kinase: immunological evidence for the existence of 
tissue-specific isoforms 
William N. Hait a, Michael D. Ward a, Ilya N. Trakht b, Alexey G. Ryazanov a,* 
~Departments ()f Pharmacology and Medicine, and The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey/ 
RobertWood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA 
blrving Center for Clinical Research, Columbia University, New York, NY 10032, USA 
Received 25 September 1996 
Abstract eEF-2 kinase is a ubiquitous CaZ+/calmodulin-de - 
pendent protein kinase that is specific for protein synthesis 
elongation factor-2 (eEF-2). This study describes an improved 
procedure for the purification of eEF-2 kinase from rabbit 
reticuiocyte lysate. The eEF-2 kinase preparation was used to 
raise polyclonal antibodies, which immunoprecipitated eEF-2 
kinase protein and activity from rabbit reticuiocyte lysate. The 
antibodies recognized a single 103 kDa band in extracts from 
several cell lines including NIH 3T3, PC12, C6 gHoma, HeLa, 
and MCF-7 breast carcinoma. However, there was no immuno- 
reactivity in extracts of rabbit or bovine liver or rabbit kidney 
despite the presence of abundant eEF-2 kinase activity in these 
tissues. Exposure of PCI2 cells to nerve growth factor (NGF) 
resulted in rapid dnwn-regulation of eEF-2 kinase activity and a 
decrease in immunoreactivity. After 24 h of incubation with 
NGF, the activity of the kinase recovered to 80% of initial 
values. In contrast, the immunoreactivity of eEF-2 kinase 
continued to decrease. These data suggest that tissue-specific 
isoforms of eEF-2 kinase may exist and that these isoforms may 
be regulated by growth factors. 
Key words: Elongation factor-2; Protein synthesis; Protein 
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1. ln~oduefion 
Elongation factor 2 kinase (eEF-2 kinase), also known as 
Ca2+/calmodulin-dependent protein kinase III, has been 
shown to phosphorylate eukaryotic elongation factor-2 
(eEF-2) with exceptional specificity reviewed in [1,2]. eEF-2 
is a 100 kDa polypeptide that catalyzes ribosomal transloca- 
tion, a reaction that results in movement of the ribosome 
along mRNA during translation. Upon phosphorylation, 
eEF-2 becomes inactive, resulting in the arrest of protein 
synthesis [3,4]. 
Phosphorylation of eEF-2 occurs during cellular stimula- 
tion by mitogens, activation of neurons, and stimulation of 
secretory cells by various secretogogues [1,2]. The activation 
of eEF-2 kinase and transient arrest of protein synthesis may 
therefore act to conserve cellular energy and/or remove short- 
lived repressors as a part of a larger signal transduction path- 
way. In addition, the activity of the kinase is markedly in- 
creased in malignant cell lines [5,6]. 
Despite the importantance of eEF-2 kinase, relatively little 
is known about its activation and regulation. Progress has 
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been hampered, at least in part, by the inability to purify 
sufficient quantities of the enzyme to raise antibodies and 
undertake detailed analysis. 
Here we describe a rapid and efficient procedure for purifi- 
cation of eEF-2 kinase. Using the purified material, we ob- 
tained polyclonal antibodies to the rabbit reticulocyte EF-2 
kinase. We used these antibodies to identify the tissue distri- 
bution and regulation of eEF-2 kinase in PCI2 cells, and 
compared these results to those obtained by measuring en- 
zyme activity. We present evidence that in several tissues of 
the rabbit and during neuronal differentiation of PC12 cells, 
there exists eEF-2 kinase activity not recognized by antibodies 
raised against rabbit reticulocyte EF-2 kinase. 
2. Materials and methods 
Rabbit reticulocyte lysate was obtained from Green Hectares, Ore- 
gon, WI. Bovine liver was obtained from Cartaret Arbitrage, Carta- 
ret, NJ. Fetal bovine serum (FBS), horse serum, DMEM, and nerve 
growth factor (NGF) were obtained from Gibco. DEAE-Sephacel and 
all buffers and chemicals were obtained from Sigma. Phenyl Sephar- 
ose and Mono-Q columns were obtained from Pharmacia. 
PC12 cells (kindly provided by Erick Morris, Robert Wood John- 
son Medical School) were cultured in DMEM containing 10% horse 
serum and 5% FBS in flasks precoated with 500 ~tg/ml collagen in 10% 
acetic acid. NIH 3T3, C6 glioma cells, and Rat Embryo Fibroblasts 
(REF) were cultured in DMEM containing 10% FBS. CV-I cells were 
cultured in EMEM with Earle's balanced salt solution containing 10% 
FBS. HeLa and MCF-7 cells were cultured in Alpha-MEM with non- 
essential amino acids containing 10% FBS. T98G cells were cultured 
in Ham's F-10/DMEM (1 : 10) plus 10% FBS. All cultures were main- 
tained in a humidified incubator at 37°C, in an atmosphere of 95% 
air, 5% CO2. Cells were checked regularly and found to be free of 
contamination by mycoplasma or fungi. 
Tissues were excised from rabbits and immediately homogenized on 
ice in Buffer D using a Dounce homogenizer; Buffer D contained 25 
mM HEPES, pH 7.4, 100 mM NaC1, 20 mM sodium pyrophosphate, 
2 mM EDTA, 3 mM EGTA, 0.5 mM PMSF, 1.25 lag/ml eupeptin, 
1.25 ~tg/ml pepstatin-A, and 2.5 ktg/ml soybean trypsin inhibitor. 
Homogenates were centrifuged in an Eppendorf centrifuge for 30 
min at 4°C and the supernatant decanted. This material was stored 
at -80°C in 100 ~tl aliquots, eEF-2 kinase was partially purified by 
adding 1 vol. of a DEAE-Sephacel slurry equilibrated in 20 mM 
Trizma base, pH 7.4, 1 mM MgC12, 10% glycerol, 7 mM ]3-mercap- 
toethanol, 2 ~tg/ml leupeptin, and 2 ~tg/ml pepstatin-A. The slurry was 
incubated at 4°C on a rotary shaker for 30 min and the Sephacel 
pelleted by gentle centrifugation. After several washes with Buffer 
D, the supernatant was decanted and an initial fraction (not contain- 
ing eEF-2 kinase) was eluted with two washes of 3 vol. of Buffer D 
containing 250 mM NaC1. The fraction containing eEF-2 kinase was 
eluted with 1 vol. (typically 100 ~tl) of Buffer D containing 500 mM 
NaC1. The yields were sufficient from this procedure to measure n- 
zyme activity and carry out immunoassays a described below. 
eEF-2 kinase was purified from rabbit reticulocyte lysate and bo- 
vine liver. The procedure was the same for both sources with mod- 
ifications as noted. Rabbit reticulocyte lysate (250 ml) was centrifuged 
at 50000×g for 30 min and added to 100 ml of a cold slurry of 
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DEAE-Sephacel quilibrated in 20 mM Trizma base, pH 7.4, 50 mM 
NaC1, 1 mM MgC12, 10% glycerol, 7 mM [3ME, 2 lag/ml eupeptin, 
and 5 lag/ml pepstatin (Buffer A). The slurry/lysate was continuously 
stirred at low speed for 30 min at 4°C. After extensive washes with 
Buffer A to remove unbound material, the slurry was poured into a 
100 ml XK-26 column (Pharmacia) and equilibrated to baseline at 
4°C on a Pharmaeia FPLC system with Buffer A. A 50-600 mM 
NaCI linear gradient in Buffer A was applied and eluted fractions 
were tested for eEF-2 kinase activity. For purification of the kinase 
from bovine liver, we used a 50-1000 mM NaC1 gradient. Fractions 
containing kinase activity were pooled, dialyzed overnight on ice 
against 20 mM Trizma base, pH 7.0, 1.0 M (NH4)2SO4, 10% glycerol, 
7 mM [3ME, 2 gg/ml eupeptin, and 5 lag/ml pepstatin (Buffer B), and 
applied to a 1.0 ml HS Phenyl Sepharose column (Pharmacia). The 
column was developed with a dual 1.0-500 mM and 500 mM-0.0 M 
(NH4)2SO4 linear gradient. Fractions containing kinase activity were 
pooled and applied irectly to a HR5/5 Mono-Q column (Pharmacia) 
equilibrated with 20 mM Trizma base, pH 7.4, 1 mM MgC12, 10% 
glycerol, 7 mM [3ME, 2 lag/ml leupeptin, and 5 lag/ml pepstatin A. The 
column was developed with a dual 0.0-300 mM and 300-700 mM 
KCI linear gradient, eEF-2 kinase was recovered as a homogeneous 
species in a total volume of 1.0 ml (Table 1). 
Phosphorylation f eEF-2 in eluted fractions and lysates was mea- 
sured in 40 lal reaction volumes containing 50 mM HEPES, pH 7.4, 10 
mM magnesium acetate, 0.1 mM CaC12, 5 mM dithiothreitol, 15 laM 
ATP, 2 laCi [T-32p]ATP, 1 lag calmodulin, 0.5 lag rabbit reticulocyte 
eEF-2, and 0.5-100 lag of sample. Reactions were initiated by adding 
the reaction mixture to the FPLC fraction or tissue sample and in- 
cubating at 30°C for 2 min. Assays were terminated by adding 20 lal 
of 3 times Laemmli sample buffer containing 150 mM Tris-HC1 (pH 
6.8), 6% SDS, 30% glycerol, 15% [3-mercaptoethanol, and 0.003°/,, 
bromphenol b ue. Samples were boiled for 5 rain and proteins epa- 
rated by 8% SDS-PAGE. Phosphoproteins were analyzed by autora- 
diography. For quantitative analysis of eEF-2 phosphorylation, gels 
were scanned by an Ambis Radioanalytic Imaging System (Ambis, 
Inc., San Diego, CA) and specific activity calculated from back- 
ground-corrected data. 
To generate antibodies, purified eEF-2 kinase was electrophoresed 
on an 8% SDS-PAGE gel and briefly stained with Coomassie blue R- 
250. The kinase band was excised (approx. 0.5 lag total protein) and 
suspended in 300 gl of PBS. This material was passed through succes- 
sively smaller bore needles until it passed easily through a 26-ga nee- 
dle. Two 4-6-week-old Balb/C mice were immunized intraperitoneally 
with 50 lal of gel suspension and then boosted twice at 7 day intervals. 
At days 8-10 after the last boost, mice were bled via a tail vein and 
sera stored at -40°C. Antibody titer was determined by immunoblot 
analysis. Control sera was obtained from the same mice 3 days prior 
to the primary immunization. 
Immunoblotting with anti-eEF-2 kinase was performed according 
to the method of Towbin et al. with minor modifications [7]. Proteins 
were separated by 8% SDS-PAGE and then transferred using a semi- 
dry electroblotting apparatus (Owl Scientific) to nitrocellulose at 13.8 
V for 2 h. The membranes were blocked in 10 ml of PBS containing 
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Table 1 
eEF-2 kinase purification from rabbit reticulocyte lysate 
Purification step Protein Specific activity Recovery 
(mg) (pmol/min/mg) (%) 
50000Xg 12915 44.9 100 
DEAE Sephacel 78.2 3174 38 
Phenyl Sepharose 3.5 37 569 20 
Mono-Q 0.033 3 x 106 16 
Protein concentration was measured by BioRad protein assay. Specific 
activity was determined by calculating ATP incorporated per minute 
per mg protein into eEF-2 using an Ambis radioanalytic imaging 
system. See Section 2 for details of the purification scheme. 
5% non-fat dry milk (NFDM) for at least 1 h. The nitrocellulose was 
incubated with anti-eEF-2 kinase antisera in PBS with 1% NFDM at 
4°C overnight. Immunoreactive protein was detected by goat anti- 
mouse antibodies conjugated to horseradish peroxidase. An ECL 
chemiluminescence detection system (Amersham) was used for antigen 
detection as per the manufacturer's protocol. Immunoprecipitations 
with control (pre-immune) and anti-eEF-2 kinase antisera were done 
by incubating 100 p.1 of sample with 30 gl of sera for 1 h at 4°C on a 
vortex shaker. Immune complexes were recovered by adding 50 gl of a 
protein G-Sepharose (Sigma) slurry and incubating as described 
above. The beads were recovered by gentle centrifugation a d washed 
3 times with PBS, boiled in Laemmli solubilizing buffer and centri- 
fuged briefly. The resulting supernatants were run on 8% SDS-PAGE 
gels and immunoblotted as described above. Immunoprecipitation 
and recovery of eEF-2 kinase activity was done as follows: samples 
were immunoprecipitated as escribed above except after incubation 
with beads, a kinase assay was performed on both the supernatant 
and the beads. In the latter case, the whole volume of Sepharose was 
incubated under standard assay conditions except hat time was ex- 
tended to 5 min. 
PC12 cells were grown in T-75 culture flasks and treated with 50 ng/ 
ml NGF for various periods of time. At the experimental times in- 
dicated, media was aspirated and cells detached by trituration with 
cold, sterile PBS containing 5 mM EDTA and washed twice by cen- 
trifugation in ice-cold PBS. Cell pellets were homogenized in a 
Dounce homogenizer in Buffer D. Homogenates were centrifuged in
an Eppendorf centrifuge for 30 min and the protein concentration f 
the supernatant was determined by BioRad protein assay. This mate- 
rial was used in both immunoblotting and eEF-2 kinase activity as- 
says. 
3.  Resu l t s  
To determine the tissue distribution of eEF-2 kinase, var- 
ious rabbit tissues were screened for eEF-2 kinase activity. 
Tissue extracts were obtained as described in Section 2. Ex- 
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Fig. 1. eEF-2 kinase activity in various rabbit tissues. Tissues were semi-purified with DEAE-Sephacel and protein concentrations adjusted to 
20 lag/5 lal. Activity was assayed as described in Section 2 and eEF-2 phosphorylation quantitated on an Ambis radioanalytic maging system. 
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Fig. 2. Purification of eEF-2 kinase from rabbit reticulocytes. A: DEAE-Sephacel chromatography of 250 ml (13 g protein) rabbit reticulocyte 
lysate. A linear gradient of 50~00 mM NaC1 was applied in 5 column volumes. (0,  eEF-2; A, eEF-2 kinase). The eEF-2 was further purified 
and used as a substrate. B: Phenyl Sepharose chromatography of DEAE-eluted material. Peak fractions were dialyzed against Buffer B prior to 
loading. C: Mono-Q chromatography of eEF-2 kinase from phenyl Sepharose fractions. Phenyl Sepharose-eluted material was applied directly 
to the column and eluted with a dual step-linear gradient as shown. 
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Fig. 3. SDS-PAGE of Mono-Q fractions from eEF-2 kinase purifi- 
cation. Fractions 24-28 were concentrated 2-fold in a Centriprep 
Concentrator (Amicon) and run on a 8% gel stained with Coomas- 
sie Blue R-250. The arrow indicates the 103 kDa eEF-2 kinase. 
eEF-2 phosphorylation assays of these fractions resulted in a corre- 
sponding peak of activity at fraction 26. 
tracts from each tissue were chromatographed on DEAE cel- 
lulose to partially purify the kinase. Fig. 1 demonstrates that 
the highest activity of eEF-2 kinase was in rabbit reticulo- 
cytes, followed by pancreas, liver, ovary, bladder, and kidney. 
Since rabbit reticulocyte lysate had the greatest specific ac- 
tivity of the kinase, we used this material for purification. 
After a 50000xg centrifugation, lysate was applied to 
DEAE-Sephacel and eluted with a linear gradient of NaC1 
(0.05~0.6 M) (Fig. 2A). The kinase was eluted as a single 
peak at approximately 0.4 M NaC1 and was well separated 
from eEF-2. Fractions containing eEF-2 kinase were pooled, 
dialyzed against Buffer B, and applied to a HS Phenyl Sephar- 
ose column• The kinase activity was eluted with a two-step 
linear (NH4)2SO4 reverse gradient (Fig. 2B) and fractions 
containing kinase activity applied directly to a Mono-Q anion 
exchange column. We found that the two-step linear gradient 
(Fig. 2C) gave the greatest separation of the kinase from other 
proteins. 
The specific activity and yield of eEF-2 kinase at each step 
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Fig. 4. lmmunoprecipitation f rabbit reticulocyte lysate eEF-2 ki- 
nase. Enzyme recovered from the second stage of the purification 
(phenyl Sepharose) was precipitated with eEF-2 kinase antisera. A: 
Recovery of eEF-2 kinase activity from the immunoprecipitates. 
Polyclonal antisera was incubated with semi-purified eEF-2 kinase. 
Immune complexes were precipitated with protein G-Sepharose. Pre- 
cipitated beads (ppt) and supernatant (sup) were incubated under 
standard kinase assay conditions (see Section 2) for 5 min. The pan- 
el is an autoradiograph of the reaction mixtures electrophoresed 
on an 8% SDS-PAGE gel. The arrow indicates phosphorylated 
eEF-2. Note that nearly all activity is recovered in the anti-eEF-2 
kinase precipitate while the control sera contains activity only in the 
non-precipitated fraction. B: An immunoblot of SDS-PAGE-sepa- 
rated immunoprecipitates. Semi-purified eEF-2 kinase was incubated 
as above with both anti-eEF-2 kinase antisera and control antisera, 
and electrophoresed on an 8% SDS-PAGE gel. Proteins were trans- 
ferred to nitrocellulose and the blot incubated with anti-eEF-2 ki- 
nase antiserum. The panel is an autoradiograph of an ECL immu- 
noblot. 
of purification are shown in Table 1. Using this procedure we 
were able to obtain approximately 30 ~tg of homogeneous 
eEF-2 kinase from 250 ml of lysate, with a yield of 16%. 
Purified eEF-2 kinase migrated as a single 103 kDa band by 
SDS-PAGE (Fig. 3). 
Antibodies were generated as described in Section 2 and 
were able to detect as little as 1.6 ng of kinase by immuno- 
blotting (data not shown). To confirm that the antibodies 
were specific for eEF-2 kinase, we performed immunoprecipi- 
tation experiments as shown in Fig. 4. Fig. 4A demonstrates 
the ability of the antibodies to immunoprecipitate enzyme 
activity, and Fig. 4B demonstrates the effects on the 103 
kDa polypeptide. These data demonstrate that the polyclonal 
antibodies immunoprecipitated EF-2 kinase and the immu- 
noprecipitated material was able to phosphorylate eEF-2. Im- 
munoprecipitation resulted in the disappearance of activity 
from the supernatant fraction. Control serum did not immu- 
noprecipitate kinase activity nor did it precipitate the 103 kDa 
polypeptide. 
We next compared the immunoreactivity of the kinase from 
several tissues and cell lines. The polyclonal antibodies readily 
detected the 103 kDa band in reticulocyte lysate but failed to 
detect this band in rabbit liver (Fig. 5A), even when equal 
amounts of eEF-2 kinase activity were loaded. In addition, 
these antibodies failed to recognize EF-2 kinase in a prepara- 
tion of purified kinase from bovine liver (Fig. 5A). 
We next studied the immunoreactivity of the kinase in eight 
human, rat, monkey and mouse cell lines. Anti-eEF-2 kinase 
antibodies detected the 103 kDa protein in extracts of several 
different cell lines (Fig. 5B), including N IH 3T3 (mouse fibro- 
blasts), HeLa (cervical carcinoma), MCF-7 (breast carcino- 
ma), T98G (human glioblastoma), C6 (rat glioblastoma), 
and PC12 cells (rat pheochromocytoma). In contrast, the anti- 
bodies failed to recognize the 103 kDa band in the trans- 
formed monkey kidney fibroblast cell line CV-1, despite the 
presence of abundant kinase activity in extract from this cell 
line. 
Treatment of PCI2 cells with NGF produces a transient 
down-regulation of eEF-2 kinase activity [12 16]. We there- 
fore studied whether or not the immunoreactivity of eEF-2 
kinase in PC12 cells was also affected by NGF.  The activity of 
the kinase declined to 5% of the initial value after 6 h of 
incubation with NGF and recovered to 80% of baseline values 
after 24 h. Immunoreactivity was also markedly decreased by 
6 h. In contrast, at 24 h, immunoreactivity continued to de- 
crease (Fig. 6B) despite the reappearance of kinase activity 
(Fig. 6A). 
Fig. 5. eEF-2 kinase activity and protein expression. A: lmmunoreactivity of eEF-2 kinase in rabbit retivculcuyte lysate, rabbit and bovine liv- 
er. Concentration of protein in reticulocyte lysate and rabbit liver extract was adjusted to load equivalent total enzyme activity in each lane. 
This required loading 3 times more protein from the rabbit liver extract compared to that of the reticulocyte lysate. The bovine liver material 
was extensively purified and at least 1 ~tg of eEF-2 kinase was used in the experiment. The proteins were separated by SDS-PAGE, transferred 
to nitrocellulose, and incubated with anti-eEF-2 kinase antiserum as described in Section 2. Immunoreactivity was assayed by ECL chemilumi- 
nescence. The arrow indicates eEF-2 kinase. B: Immunoreactivity of eEF-2 kinase from various cell lines. Tissue extracts (100 ~tg) prepared as 
described in Section 2 were assayed as in (A). REF, rat embryo fibroblasts; NIH 3T3, mouse fibroblasts; CV-1, transformed monkey kidney fi- 
broblasts; HeLa, human cervical epithelioid carcinoma; MCF-7, human breast carcinoma; PC12, rat pheochromocytoma; T989G, human glio- 
blastoma, C6, rat glioblastoma. 
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Fig. 6. Activity and immunoreactivity of eEF-2 kinase during PC12 cell differentiation. A: Equivalent protein concentrations were used in as- 
saying eEF-2 phosphorylation for untreated (0), 6, and 24 h NGF treatment. The panel is an autoradiograph of kinase assay mixtures electro- 
phoresed on 8%, SDS-PAGE. B: Immunoreactivity of eEF-2 kinase in PC12 cell lysates treated with NGF. Equivalent protein amounts of cell 
lysates from (A) were run on an 8% SDS gel, transferred to nitrocellulose and incubated with anti-eEF-2 kinase antiserum. 
4. Discussion 
In this study we describe an improved procedure for the 
purification of eEF-2 kinase from rabbit reticulocyte lysate. 
The purification of this kinase from reticulocyte lysate has 
been previously described and had been suggested to be a 
95-105 kDa polypeptide based on co-elution of kinase activity 
with a protein of within this molecular weight range [8,9]. 
Using newly generated polyclonal antibodies, we have shown 
that the 103 kDa band seen on SDS gels is eEF-2 kinase. 
The purification procedure results in the recovery of ap- 
proximately 30 [tg of enzyme from 13 g of tissue, correspond- 
ing to 16% of the kinase activity in the starting material (Ta- 
ble 1). This represents a 10-fold increase in recovery compared 
to that of previous methods [8,9]. In this procedure, DEAE 
chromatography is used initially to facilitate removal of he- 
moglobin, which can account for up to 80% of the total pro- 
tein in this tissue, and to separate the kinase from its sub- 
strate, eEF-2 (Fig. 2). The next step was purification on 
phenyl Sepharose. As shown in Fig. 2B, the majority of total 
protein is elated in the unbound fraction while eEF-2 kinase 
remains tightly bound to the matrix. This level of purification 
was aided by the Mono-Q step and the selection of the gra- 
dient depicted in Fig. 2C, which separates the kinase from 
several co-migratory proteins uch as hsp-90. The procedure 
resulted in the recovery of a single 103 kDa protein in three 
fractions as shown in Fig. 3. 
Antibodies raised against purified eEF-2 kinase precipitate 
both eEF-2 kinase activity (Fig. 4A) and eEF-2 kinase protein 
(Fig. 4B). The antibodies also recognize EF-2 kinase in cell 
lines from several species including mouse, rat, and human 
(Fig. 5). 
In contrast, the antibodies do not recognize EF-2 kinase in 
rabbit or bovine liver (Fig. 5A), despite the presence of abun- 
dant kinase activity. Although we considered several possible 
explanations for these results including interference of binding 
of antibody in different issues, or differences in levels of ex- 
pression of the kinase, these appeared unlikely since the ex- 
periments were done using partially purified materials under 
reducing conditions on SDS gels and in the presence of up to 
3 ~tg of eEF-2 kinase (Fig. 5). These data raise the possibility 
of a different isoform of the kinase in liver that might account 
for the lack of antibody recognition i  this tissue. A previous 
indication of the existence of eEF-2 kinase isoforms was pro- 
vided by Knight et al. [10], who showed that Mn 2+ stimulated 
phosphorylation of eEF-2 in the extracts of rat pancreatic 
acinar cells as well as in extract of whole pancreas, but not 
in the extracts from rat liver or kidney. 
Further data supporting the existence of isoforms of eEF-2 
kinase were obtained in PCI2 cells. Treatment of PC12 cells 
with NGF induces differentiation i to a neuronal phenotype, 
characterized by neurite outgrowth and the appearance of a 
number of molecular markers observed in sympathetic neu- 
rons [11]. More than a decade ago, Guroff and his colleagues 
studied the effect of NGF on the phosphorylation profile of 
extracts of PCI2 cells [12,13]. They found that the only ob- 
vious difference in extracts prepared several hours after NGF 
treatment in comparison with untreated cells was the reduc- 
tion in phosphorylation f eEF-2. It was found that the level 
of eEF-2 remains constant during incubation with NGF and 
the decrease in eEF-2 phosphorylation was due to down-reg- 
ulation of the kinase activity [14]. We confirmed that treat- 
ment of PC12 cells with NGF leads to the down-regulation f 
eEF-2 kinase activity (Fig. 6A), which was due to the loss of 
the kinase rather than the substrate, eEF-2. The activity of 
eEF-2 kinase recovers to about 80% of the initial value by 24 
h after incubation with NGF despite a persistant decrease in 
immunoreactivity (Fig. 6B). This is in agreement with pre- 
vious observations by Nairn et al. [16] that recovery of kinase 
activity after NGF treatment requires new protein synthesis. 
In addition, these data suggest hat the eEF-2 kinase, which 
reappears after 24 h of incubation with NGF, may represent 
an immunological variant different from that found in the 
undifferentiated cells. More detailed immunological nd mo- 
lecular studies hould reveal whether the existence of different 
isoforms of eEF-2 kinase is due to post-translational modifi- 
cations, alternative splicing, or the expression of different 
genes. 
We have recently completed the cloning and sequencing of 
cDNAs for eEF-2 kinase from C. elegans, mouse and rat 
(Ryazanov et al. manuscript in preparation). Sequence analy- 
sis failed to reveal homology to the catalytic domains of other 
members of the protein kinase superfamily, with the exception 
of myosin heavy chain kinase-A from Dictyosteliurn discoi- 
deum [17]. Redpath et al. [18] have recently reported the se- 
quencing of eEF-2 kinase from rat skeletal muscle, which is 
identical to what we have obtained from rat PC12 cells. 
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